Minimizing matrix effects in the development of a method for the determination of salmeterol in human plasma by LC/MS/MS at low pg/mL concentration levels

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):285-93. doi: 10.1016/j.jchromb.2007.06.010. Epub 2007 Jun 22.

Abstract

Salmeterol is an inhaled bronchodilator drug used for treatment of asthma. Its concentrations in plasma are very low or undetectable by previously developed methods. The present paper describes a method for analysis of salmeterol in human plasma with 2.5 pg/mL lower limit of quantitation. Despite the basic character of the drug the method uses mixed mode anion-exchange solid phase extraction for sample preparation combined with a column switching approach to minimize matrix effects. Samples are separated and detected by LC/MS/MS. The method is easy to use, only requires 0.5 mL of plasma and was validated for use in bioanalytical applications. The method does not suffer from interference from co-administered fluticasone propionate.

Publication types

  • Validation Study

MeSH terms

  • Adrenergic beta-Agonists / blood*
  • Albuterol / analogs & derivatives*
  • Albuterol / blood
  • Chromatography, High Pressure Liquid / methods*
  • Humans
  • Salmeterol Xinafoate
  • Sensitivity and Specificity
  • Spectrometry, Mass, Electrospray Ionization / methods
  • Tandem Mass Spectrometry / methods*

Substances

  • Adrenergic beta-Agonists
  • Salmeterol Xinafoate
  • Albuterol